Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.

Adv Ther · 2026 · PMC13415669 · PMID 42154367

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantP < 0.0001actually significant

The stratified log-rank test showed a highly significant difference between groups ( P < 0.0001), and the stratified Cox model produced a hazard ratio of 0.30 (95% CI 0.223–0.408), indicating a 70% lower risk of recurrence with the firsekibart group compared with the positive control.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.